N/A N=65 Addictive Potential of LCCs in Dual Users
Tobacco Use Disorder · Dual Tobacco Use · Tobacco Dependence
Primary: Demand Elasticity — 0.027; 0.032 cigarettes/dollar
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor
Acute Kidney Injury
Primary: Area Under the Curve (AUC) of Urinary Kidney Injury Biomarker Kidney Injury Molecule-1 (KIM-1) Above Baseline Within 24 Hours Postoperatively — 51.4; 52.3 ng*h/mL
N/A N=165 Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients
Heart Septal Defects, Atrial · Atrial Septal Defect
Primary: Effective Closure Rate at 360-day Post Operation — 158 Participants
Phase 3 N=1,311 A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
Short Cervical Length
Primary: Number of Participants With Delivery or Fetal Loss of Either Twin Prior to 35 Weeks Gestation — 84; 84; 86 Participants
N/A N=220 Improving Health Outcomes and Equity by Targeting Postpartum Mothers at Highest Risk
Maternal Behavior · Postpartum Depression
Primary: Emergency Department (ED) Visits and Readmissions — 18; 21 Postpartum Hospital Use
Phase 3 N=1,690 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Urinary Tract Infection · Acute Pyelonephritis
Primary: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) Population — 261; 291; 171; 179…
N/A N=132 Detection of Barrett s Esophagus in Patients Without GERD Symptoms
Barrett's Esophagus
Primary: Positive Predictive Value (PPV) of EC/EG in a Non-GERD Population That Has Three or More Non-GERD Risk Factors for BE. — 33 Percentage of screened participants
Phase 2 N=833 A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
Influenza, Human
Primary: Part 1 YA: Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer — 12.40; 54.78; 83.98; 98.65 Titers
Phase 2 N=49 Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Plasma Cell Myeloma
Primary: Rate of Minimal Residual Disease (MRD) Negative Response After Autologous Stem Cell Transplantation (ASCT) — 0.652 proportion of participants
Phase 2 N=20 Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
Peanut Allergy
Primary: The Proportion of Subjects Mildly Symptomatic or Less at the 12 Month DBPCFC — 4; 4 Participants — p=1.00
Phase 1 N=47 Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis/Bladder Pain Syndrome
Primary: Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day — -0.7; -1.6; -0.8; -1.7 score on a scale
N/A N=223 Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India
Iron Deficiency · Zinc Deficiency
Primary: Hemoglobin (g/dL) — 10.90; 10.30 g/dL
Phase 3 N=74 Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population
Local Anesthetic
Primary: Conjunctiva Anesthesia With Chloroprocaine 3% Eye Gel as Compared With Oxybuprocaine Chlorhydrate 0.4% Eye Drops — 19; 23 participants
Phase 1 N=23 Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
Bacterial Infections
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 48hours (AUC0-48) of Omadacycline After IV Infusion — 8990; 13300 hours*nanograms per…
Phase 2 N=5 Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity
Pre Diabetes
Primary: Monitoring Adverse Events — 0; 0 TEAE